Cowen Reiterates Outperform on Celgene (CELG) Following a Soft 3Q
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Nasdaq leads Wall Street lower on AI spending jitters; oil prices rebound
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
Celgene Reports Third Quarter 2015 Operating and Financial Results
November 5, 2015 7:31 AM ESTOver 150 Abstracts Expected at Medical Congresses in Fourth Quarter Completed Two Major Transactions in the Quarter: Receptos and Juno Therapeutics Key Drivers On-Track Supporting Industry-Leading Growth Including Acceleration of Mid- and Late-Stage Clinical Programs
SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ: CELG) reported net product sales of $2,313 million for the third quarter of 2015, an 18 percent increase from the same period in 2014. The negative net impact of currency on net product sales was 2 percent. Third quarter... More



